Search

Hoffman IF, Taha TE, Padian NS, Kelly CW, Welch JD, Martinson FE, Kumwenda NI, Rosenberg ZF, Chilongozi DA, Brown JM, Chirenje M, Richardson BA. Nonoxynol-9 100 mg gel: multi-site safety study from sub-Saharan Africa. 2004. 18. 2191-5. .

Metzger DS, Koblin B, Turner C, Navaline H, Valenti F, Holte S, Gross M, Sheon A, Miller H, Cooley P, Seage GR 3rd. Randomized controlled trial of audio computer-assisted self- interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. 2000. 152. 99-106. .

Baeten JM, Richardson BA, Martin HL Jr, Nyange PM, Lavreys L, Ngugi EN, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials. 2000. 24. 458-64. .

Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, Davis C, Kennedy J, Fairman J, Foley B, Kop J. Sensitivity and specificity of the ViroSeq® HIV-1 Genotyping System for detection of HIV-1 drug resistance mutations using an ABI PRISM® 3100 Genetic Analyzer. 2005. 43. 813-17. PMC 548107.

Seage GR 3rd, Holte SE, Metzger D, Koblin BA, Gross M, Celum C, Marmor M, Woody G, Mayer KH, Stevens C, Judson FN, McKirnan D, Sheon A, Self S, Buchbinder SP. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. 2001. 153. 619-27. .

Silverthorn CF, Parsons TL. A validated new method for nevirapine quantitation in human plasma via high-performance liquid chromatography. 2006. 20. 23-7 PMID: 15920701. .

Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B; the HPTN 055 Study Team. The Value of Site Preparedness Studies for Future Implementation of Phase 2/IIb/III HIV Prevention Trials: Experience From the HPTN 055 Study. 2008. 47. 93-100.. .

Safren SA, Kumarasamy N, Hosseinipour M, Harwood MM, Hoffman I, McCauley M, Jumbe A, Nyirenda C, Mimiaga MJ, Solomon S, Celentano D, Mayer KH. Perceptions about the acceptability of assessments of HIV medication adherence in Lilongwe, Malawi and Chennai, India. 2006. 10. 443-50 PMID:16604297. .

Chingono A, Lane T, Chitumba A, Kulich M, Morin S. Balancing science and community concerns in resource-limited settings: Project Accept in rural Zimbabwe. 2008. 5. 273-6 PMID:18559417. .

Vermund SH. Vaccine efficacy trials for human immunodeficiency virus/acquired immunodeficiency syndrome are feasible in the United States: a commentary on the HIVNET Vaccine Preparedness Study. 2001. 153. 630-1. .

Kapina M, Reid C, Roman K, Cyrus-Cameron E, Kwiecien A, Weiss S, Vermund SH. HIV Incidence Rates and Risk Factors for Urban Women in Zambia: Preparing for a Microbicide Clinical Trial. 2009. 36. 129-33. PMC2889146.

Forman MS, Valsamakis A. Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total nucleic acid isolation and COBAS taqman hepatitis C virus analyte-specific reagent. 2008. 10. 147-53.. PMC2259469.

Morin SF, Morfit S, Maiorana A, Aramrattana A, Goicochea P, Mutsambi JM, Robbins JL, Richards TA. Building community partnerships: case studies of Community Advisory Boards at research sites in Peru, Zimbabwe, and Thailand. 2008. 5. 147-56 PMID:18375653. .

Chirowodza A, van Rooyen H, Joseph P, Sikotoyi S, Richter L, Coates T. Using Participatory Methods and Geographic Information Systems (Gis) to Prepare for an HIV Community-based Trial in Vulindlela, South Africa (Project Accept-HPTN 043. 2009. 37. 41-57. PMC2747527.

Maman S, Lane T, Ntogwisangu J, Motholo T, Sikotoyi S, Visrutaratna S, Fritz K, Chitumba A. Using participatory mapping to inform the research and intervention design of a multi-site community-randomized trial of community-based HIV counseling and testing. 2009. 21. 368-387 (Journal Field Methods is not a PMC Journal). .

Woody G, VanEttne-Lee ML, McKirnan D, Donnell D, Seage G, Gross M. Substance Use Among Men who have Sex with Men: Comparison with a National Household Survey. 2001. 27. 86-90. .

Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. 2012. 7. 99-105. PMC3486734.

Caliendo AM, Valsamakis A, Bremer JW, Ferreira-Gonzalez A, Granger S, Sabatini L, Tosongalis GJ, Wang YF, Yen-Lieberman B, Young S, Lurain NS. Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification. 2011. 49. 2854-58. PMC3147738.

Gaydos CA, Farshy C, Barnes M, Quinn N, Agreda P, Rivers CA, Schwebke J, Papp J. Can mailed swab samples be dry-shipped for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by nucleic acid amplification tests?. 2012. 73. 16-20. PMC3425852.

van Rooyen H, McGrath N, Chirowodza A, Joseph P, Fiamma A, Gray G, Richter L, Coates T. Mobile VCT: Reaching Men and Young People in Urban and Rural South African Pilot Studies (NIMH Project Accept, HPTN 043). 2013. 17. 2946-53. PMC3597746.

Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?. 2013. 63. S122-9. PMC3710117.

Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. 2013. 63. S130-4. PMC3725298.

Sugarman J, Mayer KH. Ethics and pre-exposure prophylaxis for HIV infection. 2013. 63. S135-9. PMC3728665.

Koblin BA, Andrasik M, Austin J. Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions. 2013. 63. S183-6. PMC3737568.

Magnus M, Franks J, Griffith S, Arnold MP, Goodman K, Wheeler DP; for the HPTN 061 Study Group, Wheeler DP, HPTN 061 Study Group. Engaging, Recruiting, and Retaining Black Men Who Have Sex With Men in Research Studies: Don't Underestimate the Importance of Staffing-Lessons Learned From HPTN 061, the BROTHERS Study. 2014. 20. E1-9. PMC4167976.

Marzinke M, Breaud A, Parsons TL, Cohen MS, Piwowar-Manning E, Eshleman SH, Clarke W. The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. 2014. 10. 157-68. PMC4039613.

Maman S, van Rooyen H, Groves AK. HIV status disclosure to families for social support in South Africa (NIMH Project Accept/HPTN 043). 2014. 26. 226-32. PMC4074900.

Gaydos C, Hardick J. Point of care diagnostics for sexually transmitted infections: perspectives and advances. 2014. 12. 657-72. PMC4065592.

Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). 2016. 32. 32-43. PMC4692123.

Laeyendecker O, Redd AD, Nason M, Longosz AF, Karim QA, Naranbhai V, Garrett N, Eshleman SH, Abdool Karim SS, Quinn TC. Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. 2015. 212. 754-9. PMC4539904.

Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, Marmor M, Bozeman S, Grant RM, Flores J, Sheppard HW. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. 2001. 183. 23-35. .

K. Rivet Amico, Melissa Wallace, Linda-Gail Bekker, Surita Roux, Millicent Atujuna, Elaine Sebastian, Bonnie J. Dye, Vanessa Elharrar, Robert M. Grant, Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, Dye BJ, Elharrar V, Grant RM. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. 2017. 21. 1361-1375. PMC5378745.

Gross M, Buchbinder SP, Celum C, Heagerty P, Seage GR, 3rd. Rectal microbicides for U.S. gay men. Are clinical trials needed? Are they feasible? HIVNET Vaccine Preparedness Study Protocol Team.. 1998. 25. 296-302. .

Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM, for the HPTN 067/ADAPT Cape Town study team. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. 2018. 5. e68-e78. PMC6107917.

Franks J, Hirsch-Moverman Y, Loquere AS, Amico KR, Grant RM, Stirratt M, Dye BJ, Rivera Y, Gamboa R, Mannheimer SB. Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. 2018. 22. 1139-1149. PMC5878834.

Koblin BA, Heagerty P, Sheon A, Buchbinder S, Celum C, Douglas JM, Gross M, Marmor M, Mayer K, Metzger D, Seage G. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. 1998. 12. 785-93. .

Stone E, Heagerty P, Vittinghoff E, Douglas JM, Koblin BA, Mayer KH, Celum CL, Gross M, Woody GE, Marmor M, Seage GR, Buchbinder SP, Douglas JM Jr, Seage GR 3rd. Correlates of condom failure in a sexually active cohort of men who have sex with men. 1999. 20. 495-501. .

Woody GE, Donnell D, Seage GR, Metzger D, Marmor M, Koblin BA, Buchbinder S, Gross M, Stone B, Judson FN. Non-injection substance use correlates with risky sex among men having sex with men: data from HIVNET. 1999. 53. 197-205. .

Ojeda VD, Amico KR, Hughes JP, Wilson E, Holtz TH, Chitwarakorn A, Grant RM, Dye BJ, Bekker L-G, Mannheimer S, Marzinke M, Hendrix CW. Associations Between Research Staff-Participant Interactions and HIV PrEP Adherence in HPTN 067. 0. . . .

Gross M, Buchbinder SP, Holte S, Celum CL, Koblin BA, Douglas JM, Jr. Use of reality female condoms for anal sex by US men who have sex with men. HIVNET Vaccine Preparedness Study Protocol Team. 1999. 89. 1739-41. .

Sivay MA, Zhang Y, Hudelson SE, Li M, Piwowar-Manning E, Marzinke MA, Bokoch K, Grant RM, Eshleman SH, Amico RK, Redd A, Hendrix CW, Anderson PL, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, HPTN 067/ADAPT Study Team. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. 2017. 75. 271-279. PMC5472493.

Robert M Grant, Sharon Mannheimer, James P Hughes, Yael Hirsch-Moverman, Avelino Loquere, Anupong Chitwarakorn, Marcel E Curlin, Maoji Li, K Rivet Amico, Craig W Hendrix, Peter L Anderson, Bonnie J Dye, Mark A Marzinke, Estelle Piwowar-Manning, Laura McKinstry, Vanessa Elharrar, Michael Stirratt, James F Rooney, Susan H Eshleman, Janet M McNicholl, Frits van Griensven, Timothy H Holtz, Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH. Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. 2018. 66. 1712-1721. PMC5961078.

Mitchell KM, Dimitrov D, Hughes JP, Xia F, Donnell D, Amico KR, Bokoch K, Chitwarakorn A, Bekker LG, Holtz TH, Mannheimer S, Grant RM, Boily MC. In what circumstances could non-daily pre-exposure prophylaxis for HIV substantially reduce program costs?. 2018. 32. 809-818. PMC5854532.

Kapadia SN, Wu C, Mayer KH, Wilkin TJ, Amico KR, Landovitz RJ, Andrade A, Chen YQ, Chege W, McCauley M, Gulick RM, Schackman BR. No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. 2018. 13. e0206577. PMC6306196.

Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Siegel M, Manabe YC, Frank I, Ho K, Santana J, Stekler JD, Swaminathan S, McCauley M, Hodder S, Mayer KH. Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. 2017. 167. 384-393. PMC5667908.

McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. 2019. 33. 237-246. .

Figueroa DB, Madeen EP, Tillotson J, Richardson P, Cottle L, McCauley M, Landovitz RJ, Andrade A, Hendrix CW, Mayer KH, Wilkin T, Gulick RM, Bumpus NN. Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. 2018. 34. 421-429. PMC5934973.

Hightow-Weidman LB, Magnus M, Beauchamp G, Hurt CB, Shoptaw S, Emel L, Piwowar-Manning E, Mayer KH, Nelson LE, Wilton L, Watkins P, Whitfield D, Fields SD, Wheeler D. Incidence and Correlates of STIs among Black Men who have Sex with Men Participating in the HPTN 073 PrEP Study. 2019. 69. 1597-1604. PMC6792108.

Wheeler DP, Fields SD, Beauchamp G, Chen YQ, Emel LM, Hightow-Weidman L, Hucks-Ortiz C, Kuo I, Lucas J, Magnus M, Mayer KH, Nelson LE, Hendrix CW, Piwowar-Manning E, Shoptaw S, Watkins P, Watson CC, Wilton L. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. 2019. 22. e25223. PMC6376611.

Zhang Y, Clarke W, Marzinke MA, Piwowar-Manning E, Beauchamp G, Breaud A, Hendrix CW, Cloherty GA, Emel L, Rose S, Hightow-Weidman L, Siegel M, Shoptaw S, Fields SD, Wheeler D, Eshleman SH. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Pre-exposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.. 2017. 61. . PMC5487665.

Mannheimer S, Hirsch-Moverman Y, Franks J, Loquere A, Hughes JP, Li M, Amico KR, Grant RM. Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. 2019. 80. 551-558. PMC6417801.

Amico KR, Ramirez C, Caplan MR, Montgomery BE, Stewart J, Hodder S, Swaminathan S, Wang J, Darden-Tabb NY, McCauley M, Mayer KH, Wilkin T, Landovitz RJ, Gulick R, Adimora AA, HPTN 069/A5305 Study Team, HPTN Women at Risk Committee. Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. 2019. 22. e25247. PMC6416666.

Lancaster KE, Miller WC, Kiriazova T, Sarasvita R, Bui Q, Ha TV, Dumchev K, Susami H, Hamilton EL, Rose S, Hershow RB, Go VF, Metzger D, Hoffman IF, Latkin CA. Designing an Individually Tailored Multilevel Intervention to Increase Engagement in HIV and Substance Use Treatment Among People Who Inject Drugs With HIV: HPTN 074. 2019. 31. 95-110. .

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Margaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. 2017. 9. . PMC5714515.

Gaydos CA, Klausner JD, Pai NP, Kelly H, Coltart C, Peeling RW. Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men. 2017. 93. S31-S35. PMC5723541.

Gaydos CA, Schwebke J, Dombrowski J, Marrazzo J, Coleman J, Silver B, Barnes M, Crane L, Fine P. Clinical performance of the Solana(R) Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women. 2017. 17. 303-306. PMC5615814.

National Institutes of Health. Interventions to prevent HIV risk behaviors. National Institutes of Health Consensus Development Conference Statement February 11-13, 1997. 2000. 14 Suppl 2. S85-96. .

Ojeda VD, Amico KR, Hughes JP, Wilson E, Li M, Holtz TH, Chitwarakorn A, Grant RM, Dye BJ, Bekker LG, Mannheimer S, Marzinke M, Hendrix CW. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study. 2019. 82. 34-40. .

Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, Curlin M, Holtz TH, Mannheimer S, Marzinke MA, Amico KR, Liu A, Piwowar-Manning E, Eshleman SH, Dye BJ, Gandhi M, Grant RM, HPTN 067/ADAPT Study Team. Short and long-term pharmacologic measures of HIV pre-exposure prophylaxis use among high-risk men who have sex with men in HPTN 067/ADAPT. 0. . . .

Chemnasiri T, Varangrat A, Amico KR, Chitwarakorn A, Dye BJ, Grant RM, Holtz TH, HPTN 067/ADAPT Study Team. Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study. 2019. . 1-6. .

Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, Donnell DJ, Mannheimer S, Holtz TH, Grant RM, Boily MC. Predicted Effectiveness of Daily and Non-Daily PrEP for MSM Based on Sex and Pill-Taking Patterns from HPTN 067/ADAPT. 2019. . . .

Giovenco, D, Pettifor, A, MacPhail, C, Kahn, K, Wagner, R, Piwowar-Manning, E, Wang, J, Hughes, J. Assessing risk for HIV infection among adolescent girls in South Africa: an evaluation of the VOICE risk score (HPTN 068). 2019. 22. e25359. PMC6661402.

Tolley, EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, Pathak S, Bekker LG, Swaminathan S, Stanton J, Farrior J, Sista N. Acceptability of a Long-Acting Injectable HIV Prevention Product Among US and African Women: Findings from a Phase 2 Clinical Trial (HPTN 076). 0. 22. e25408. PMC6813716.

Sugarman J, Barnes M, Rose S, Dumchev K, Sarasvita R, Viet HT, Zeziulin O, Susami H, Go V, Hoffman I, Miller WC. Development and Implementation of Participant Safety Plans for International Research with Stigmatised Populations [HPTN 074]. 2018. 5. 468-472. PMC6889082.

Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, Mangxilana N, Nobula L, Bulterys MA, Atujuna M, Hosek S, Heffron R, Bekker LG, Mgodi N, Chirenje M, Delany-Moretlwe S, HPTN 082 study group. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. 2020. 22. e25463. PMC7060297.

Moore JR, Donnell DJ, Boily MC, Mitchell KM, Delany-Moretlwe S, Bekker LG, Mgodi NM, El-Sadr W, Cohen MS, Celum CL, Dimitrov D. Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression [HPTN 082]. 2020. 85. 423-429. PMC7670079.

Fogel JM, Sivay MV, Cummings V, Wilson EA, Hart S, Gamble T, Laeyendecker O, Fernandez RE, Del Rio C, Batey DS, Mayer KH, Farley JE, McKinstry L, Hughes JP, Remien RH, Beyrer C, Eshleman SH. HIV Drug Resistance in a Cohort of HIV-infected MSM in the United States [HPTN 078]. 2020. 34. 91-101. PMC7144622.

Bauman LJ, Mellins CA, Klitzman R. Whether to Waive Parental Permission in HIV Prevention Research Among Adolescents: Ethical and Legal Considerations [HPTN 078]. 2020. 48. 188-201. PMC8367279.

Bekker LG, Li S, Pathak S, Tolley EE, Marzinke MA, Justman JE, Mgodi NM, Chirenje M, Swaminathan S, Adeyeye A, Farrior J, Hendrix CW, Piwowar-Manning E, Richardson P, Eshelman SH, Redinger H, Williams P, Sista ND, HPTN 076 Study Team. Safety and Tolerability of Injectable Rilpivirine La in Hptn 076: A Phase 2 Hiv Pre-Exposure Prophylaxis Study in Women.. 0. . . PMC7139112.

Whitfield DL, Beauchamp G, Fields S, Nelson L, Magnus M, Dacus JD, Paul J, Anderson P, Wheeler D. Risk Compensation in HIV Prep Adherence among Black Men Who Have Sex with Men in HPTN 073 Study. 2021. 33. 633-638. PMC7902733.

Sheppard HW, Celum CL, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP. HIV-1 infection in individuals with the CCR5-delta32/delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. 2002. 29. 307-13. .

Velloza J, Heffron R, Amico KR, Rowhani-Rahbar A, Hughes JP, Li M, Dye BJ, Celum C, Bekker LG, Grant RM, Team HAS. The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT. 2020. 24. 2178-2187. PMC7319871.

Holtz TH, Chitwarakorn A, Hughes JP, Curlin ME, Varangrat A, Li M, Amico KR, Mock PA, Grant RM, Thai HAST. HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013. 2019. 82. e18-e26. PMC6742570.

Dangerfield DT, Kuo I, Magnus M, Beauchamp G, Fields S, Nelson L, Shoptaw S, Wilton L, Wheeler DP. Sexual Risk Profiles Among Black Sexual Minority Men: Implications for Targeted PrEP Messaging [HPTN 073]. 2021. 50. 2947-2954. PMC9529079.

Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, Donnell DJ, Mannheimer S, Holtz TH, Grant RM, Boily MC. Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study. 2020. 71. 249-255. PMC7353329.

S Raquel Ramos, Geetha Beauchamp, Darrell Wheeler, Leo Wilton, Darren Whitfield, Donte Boyd, Lisa Hightow-Weidman, Sheldon Fields, LaRon Nelson. Optimizing PrEP Continuance: A Secondary Analysis Examining Perceived Autonomy Support and Care Coordination Quality among Black MSM in HPTN 073. 2022. 19. 4489. PMC9026517.

Connie Celum ,Sybil Hosek,Mandisa Tsholwana,Sheetal Kassim,Shorai Mukaka,Bonnie J. Dye,Subash Pathak,Nyaradzo Mgodi,Linda-Gail Bekker,Deborah J. Donnell,Ethan Wilson,Krista Yuha,Peter L. Anderson,Yaw Agyei,Heather Noble,Scott M. Rose,Jared M. Baeten,Jessi, C Celum, S Hosek, M Tsholwana, S Kassim, S Mukaka, B J. Dye, S Pathak, N Mgodi, LG Bekker, D J. Donnell, E Wilson, K Yuha, P L. Anderson, Y Agyei, H Noble, S M. Rose, J M. Baeten, J M. Fogel, A Adeyeye, L Wiesner, J Rooney, S Delany-Moretlwe, Celum C, Tsholwana M, Kassim S, Mukaka S, Dye BJ, Pathak S, Mgodi N, Bekker LG, Donnell DJ, Wilson E, Yuha K, Anderson PL, Agyei Y, Noble H, Rose SM, Baeten JM, Fogel JM, Adeyeye A, Wiesner L, Rooney J, Delany-Moretlwe S. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. 2021. 18. e1003670. PMC8253429.

Velloza J, Donnell D, Hosek S, Anderson PL, Chirenje ZM, Mgodi N, Bekker LG, Marzinke MA, Delany-Moretlwe S, Celum C. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomized controlled trial.. 2022. 9. e680-e689. PMC9530001.

Whitfield DL, Nelson LE, Komarek A, Turner D, Ni Z, Boyd DT, Taggart T, Ramos SR, Wilton L, Beauchamp GG, Hightow-Weidman L, Shoptaw SJ, Magnus M, Mayer KH, Fields SD, Wheeler DP, Team HIVPTNS. Implementation of Client-Centered Care Coordination for HIV Prevention with Black Men Who Have Sex with Men: Activities, Personnel Costs and Outcomes– HPTN 073. 2023. 10. 183-192. PMC9441015.

Moshoette T, Papathanasopoulos MA, Killick MA. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. 2022. 19. 143. PMC9450465.

Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L, Landovitz RJ, Clement ME, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamani J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B, Team HS. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women [HPTN 083]. 2021. 385. 595-608. .

Yu Y, Bigos KL, Marzinke MA, Landovitz RJ, McCauley M, Ford S, Hendrix CW, Bies RR, Weld ED, HPTN 077 Study Team. A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP.. 2022. 88. 4623-4632. .

Jeremy Sugarman, Deborah J Donnell, Brett Hanscom, Marybeth McCauley, Beatriz Grinsztejn, Raphael J Landovitz, Sugarman J, Donnell DJ, Hanscom B, McCauley M, Grinsztejn B, Landovitz RJ. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. 2021. 8. e723-e728. .

Nelson LE, Boyd DT, Beauchamp G, Emel L, Wilton L, Whitfield D, Ramos SR, Ajiboye W, Hill MJ, Conserve DF, Thomas P, Hightow-Weidman L, Shoptaw S, Magnus M, Mayer KH, Piwowar-Manning E, Fields SD, Wheeler DP, HPTN 073 Study Team. Freedom as Prevention: Mechanisms of Autonomy Support for Promoting HIV Pre-Exposure Prophylaxis Use and Condom Use among Black MSM in 3 US Cities-HPTN 073. 0. . . .

Velloza J, Hosek S, Donnell D, Anderson PL, Chirenje M, Mgodi N, Bekker LG, Delany-Moretlwe S, Celum C. Assessing Longitudinal Patterns of Depressive Symptoms and the Influence of Symptom Trajectories on Hiv Pre-Exposure Prophylaxis Adherence among Adolescent Girls in the Hptn 082 Randomized Controlled Trial. 2021. 24. e25731. PMC8222844.

Pilgrim NA, Evans TM, Czarnogorski M. A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Pre-Exposure Prophylaxis for HIV Prevention. 2022. 23. 912-915. .

Scorgie F, Khoza N, Delany-Moretlwe S, Velloza J, Mangxilana N, Atujuna M, Chitukuta M, Matambanadzo KV, Hosek S, Makhale L, Celum C. Narrative Sexual Histories and Perceptions of Hiv Risk among Young Women Taking Prep in Southern Africa: Findings from a Novel Participatory Method. [HPTN 082]. 2021. 270. 113600. PMC8643882.

Mayer KH, Yuhas K, Amico KR, Wilkin T, Landovitz RJ, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Cottle LM, Marcus C, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu AY, Frank I, Ho K, Santana J, Stekler JD, Chen YQ, McCauley M, Gulick RM, HPTN 069/ACTG 5305 Study Team. Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). 0. . . .

Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC, group Hs. Cabotegravir for the Prevention of HIV-1 in Women: Results from Hptn 084, a Phase 3, Randomised Clinical Trial. 2022. 399. 1779-1789. PMC9077443.

Brown TT, Yuhas K, Mayer KH, Landovitz RJ, Marzinke MA, Hendrix CW, Chen YQ, Klingman KL, Chege W, Mccauley MB, Gulick RM, Wilkin TJ. Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. 2022. 77. 500-506. PMC9097256.

Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis [HPTN 083]. 2022. 175. 479-489. .

Hughes JP, Williamson BD, Krakauer C, Chau G, Ortiz B, Wakefield J, Hendrix C, Amico KR, Holtz TH, Bekker LG, Grant R. Combining information to estimate adherence in studies of pre-exposure prophylaxis for HIV prevention: Application to HPTN 067. 2022. 41. 1120-1136. PMC8881405.

Eshleman SH, Fogel JM, Halvas EK, Piwowar-Manning E, Marzinke MA, Kofron R, Wang Z, Mellors J, McCauley M, Rinehart AR, Clair MS, Adeyeye A, Hinojosa JC, Cabello R, Middelkoop K, Hanscom B, Cohen MS, Grinsztejn B, Landovitz RJ, HPTN 083 Study Team. HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention. 0. . . .

Mitchell K, Dimitrov D, Hughes J, Moore M, Vittinghoff E, Liu A, Cohen M, Beyrer C, Donnell D, Boily MC. Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials. 2020. 33. . .

Anderson PL, Marzinke MA, Glidden DV. Updating the adherence-response for oral F-TDF for PrEP among cisgender women. 2023. 76. 1850-1853. PMC10209433.

Boyd DT, Nelson LE, Hill MJ, Whitfield D, Ramos SR, Akyirem S, Emel L, Wilton L, Hightow-Weidman L, Shoptaw S, Magnus M, Mayer KH, Piwowar-Manning E, Wallace SE, Fields SD, Wheeler DP. Examining the Role of Autonomy Support, Goal Setting, and Care Coordination Quality on HIV PrEP Adherence in Black Men Who Have Sex with Men: HPTN 073. 2023. 37. 22-30. .

Stansfield SE, Moore M, Boily MC, Hughes JP, Donnell DJ, Dimitrov DT. Estimating benefits of using on-demand oral prep by MSM: A comparative modeling study of the US and Thailand. 2022. 56. . PMC9813675.

Delany-Moretlwe S, Mgodi N, Bekker L, et al. High prevalence and incidence of gonorrhoea and chlamydia in young women eligible for HIV pre-exposure prophylaxis in South Africa and Zimbabwe: results from the HPTN 082 trial. 0. . . .

Connie Celum. Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study. 2023. 18. e0281728. PMC9956790.

Gross M, Holte SE, Marmor M, Mwatha A, Koblin BA, Mayer KH. Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team. 2000. 24. 393-8. .

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women. 2023. . . PMC10292682.

Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis. 2023. . . PMC10339001.

Delany-Moretlwe S, Mgodi N, Bekker LG, Baeten JM, Li C, Donnell D, Agyei Y, Lennon D, Rose SM, Mokgatle M, Kassim S, Mukaka S, Adeyeye A, Celum C. High prevalence and incidence of gonorrhoea and chlamydia in young women eligible for HIV pre-exposure prophylaxis in South Africa and Zimbabwe: results from the HPTN 082 trial. 2023. 99. 433-439. PMC10555488.

Coletti A, Heagerty P, Sheon A, Gross M, Koblin B, Metzger D, Seage G. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine trials. 2003. 32. 161-9. .

Donnell D, Gao F, Hughes JP, Hanscom B, Corey L, Cohen MS, Edupuganti S, Mgodi N, Rees H, Baeten JM, Gray G, Bekker LG, Hosseinipour M, Delany-Moretlwe S. Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.. 2023. 26. . PMC10292682.

Jason E. Farley, Geetha Beuchamp, Alanna J. Bergman, James P. Hughes, D. Scott Batey, Carlos del Rio, Julia Raifman, Kelly Lowensen, Theresa Gamble, Robert H. Remien, Chris Beyrer. The impact of stigma and sexual identity on PrEP awareness and use among at-risk men who have sex with men in four U.S. cities (HPTN 078). Stigma and Health. Advance online publication.. 2024. 9. 400-410. PMC11323033.

Meyer D, Lowensen K, Perrin N, et al, Diane Meyer ,Kelly Lowensen,Nancy Perrin,Ayana Moore,Shruti H. Mehta,Cheryl R. Himmelfarb,Thomas V. Inglesby,Jacky M. Jennings,Alexandra K. Mueller,Jessica N. LaRicci,Woudase Gallo,Adam P. Bocek,Jason E. Farley. An evaluation of the impact of social and structural determinants of health on forgone care during the COVID-19 pandemic in Baltimore, Maryland. 2024. . . .

Sandfort TGM, Kreniske P, Mbeda C, Reynolds D, Tshabalala G, Madiwati B, Ogendo A, Dominquez K, Panchia R, Gondwe D, Hamilton EL, Guo X, Cummings V. Interest in I-PrEP and Willingness to Participate in Clinical Trials Among Men and Transfeminine Persons Who have Sex with Men in Sub-Saharan Africa: Quantitative and Qualitative Findings from HPTN 075. 2024. . 2361-2377. PMC11199096.

Beauchamp G, Hosek S, Donnell D, Chan KCG, Anderson PL, Dye BJ, Mgodi N, Bekker LG, Delany-Moretlwe S, Celum C; HPTN 082 study team. The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082. 2024. 5. 1512-1521. PMC11069481.

David Goodman-Meza, Steven Shoptaw, Brett Hanscom, Laramie R. Smith, Philip Andrew, Irene Kuo, Jordan E. Lake, David Metzger, Ellen A. B. Morrison, Melissa Cummings, Jessica M. Fogel, Paul Richardson, Jayla Harris, Jesse Heitner, Sarah Stansfield & Nabila. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study). 0. 25. 124. PMC10870682.

Landovitz RJ, Delany-Moretlwe S, Fogel JM, Marzinke MA, Piwowar-Manning E, Richardson P, Halvas EK, Mellors JW, Persaud D, Kofron R, McCauley M, Rose S, Rinehart AR, Rooney JF, Adeyeye A, Cohen MS, Donnell D, Hosseinipour MC, Grinsztejn B, Eshleman SH; HP. Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis. 2024. 391. 1253-1256. PMC11598663.

Fogel JM, Piwowar-Manning E, Moser A, Hill T, Ahmed S, Cummings V, Mostafa HH, Wang Z, Jennings A, Gallardo-Cartagena JA, Figueroa MI, St Clair M, Rinehart AR, Adeyeye A, Rooney JF, Cohen MS, Grinsztejn B, Landovitz RJ, Eshleman SH; HPTN 083 Study Team.. Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis. 0. 12. . PMC11302132.

Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, Coelho LE, Phanuphak N, Singh Y, Middelkoop K, Griffith S, McCauley M, Rooney J, Rinehart AR, Clark J, Go V, Sugarman J, Fields SD, Adeyeye A, Grinsztejn B, Landovitz RJ, Safren SA; HPTN 083‐02 S. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study. 2024. 27. e26252. PMC11116478.

Han K, Patel P, McCallister S, Rinehart AR, Gandhi Y, Spreen W, Landovitz RJ, Delany-Moretlwe S, Marzinke MA, McKeon T, Budnik P, van Wyk J, Ford SL. Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. 0. . . .

Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. 2024. 42. 447-461. PMC10937761.

Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP,. Efficacy & safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men & transgender women who have sex with men 1 year after study unblinding. 2023. 10. e767-e778. PMC11375758.

Amico KR, Mayer KH, Landovitz RJ, Marzinke M, Hendrix C, McCauley M, Wilkin T, Gulick R; HPTN 069/A5305 study team. Influence of Participant Perceptions of Adherence-Related Interactions with Study/Study Team on Drug Levels: HPTN069 Analysis of Self-Reported Adherence Experiences While on Study. 2024. 28. 1058-1067. PMC10896804.

Sharma I, Hill A. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis. 2024. 78. 386-394. PMC10874262.

Stranix-Chibanda L, Hamilton EL, Ngo J, Jiao Y, Hanscom B, Choudhury RP, Agyei Y, Piwowar-Manning E, Marzinke M, Delany-Moretlwe S, Mgodi N, Siziba B, Naidoo I, Gati Mirembe B, Kamira B, McCoig C, Adeyeye A, Spiegel HML, Hosek S; HPTN 084-01 Protocol Team. Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial. 2025. 12. e252-e260. PMC11961543.

Magongo M, Mhlanga N, Nobanda S, Chasakara C, Yola N, Hinson K, Bryan M, Mzizi P, Essien T, Hastings N, Ndimande-Khoza MN, Bekker LG, Mgodi N, Celum C, Delany-Moretlwe S. Engagement of adolescent girls and young women into an early oral PrEP open-label study in Southern Africa: lessons learned from HPTN 082. 2025. 25. . PMC12625398.

Beyrer C, Remien RH, Eshleman SH, Gamble TR, De Dieu Tapsoba J, Labbett RL, Sullivan PA, Laeyendecker O, Anderson PL, Agravat D, Hughes JP, Driffin DD, Hutchinson CS, Hucks-Ortiz C, Adair M, Curry M, Jones SB, Haddock IL, Boyd D, Burwen DR, Johnson AS, Ne. Investigating the HIV epidemic among Black gay and bisexual men in the Southern United States: Results of the HPTN 096 pilot cross-sectional assessment. 2025. 20. . PMC12533853.

Ssemambo PK, Burton M, Mirembe BG, Nakabiito C, Donnell D, Beauchamp G, Delany-Moretlwe S, Celum C, Velloza J.. Correlates of long-acting reversible contraceptive (LARC) use among young women in Southern Africa: a secondary analysis from HPTN 082. 2025. . . PMC12458495.

Brown TT, Arao RF, Warsi M, Phanuphak N, Vasconcelos R, Oyedele T, Sullivan PA, Hanscom B, Rooney JF, Rinehart AR, McCauley M, Grinsztejn B, Landovitz RJ.. Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083. 0. . . PMC12249367.

Hlahla K, Choudhury RP, Siziba B, Anderson PL, Delany-Moretlwe S, Ndzhukule TR, Hosek S, Mgodi NM; on behalf of the HPTN 082 Study Team. Association between substance use and PrEP adherence among adolescent girls and young women enrolled in an HIV prevention study in Southern Africa. 2025. 5. . PMC12176117.

Rutstein SE, Limarzi-Klyn L, Chen JS, Agyei YO, Ahmed S, Bell I, Cohen M, Fogel JM, Go V, Haines D, Hamilton EL, Hoffman IF, Hosseinipour MC, Marzinke MA, Miller WC, Mukatipa M, Pulerwitz J, Spiegel HML, Ye T, Matoga M.. Improving HIV Prevention Among Heterosexual Men Seeking Sexually Transmitted Infection Services in Malawi: Protocol for a Type I Effectiveness-Implementation Hybrid Randomized Controlled Trial (HPTN 112-NJIRA Study). 2025. 14. . PMC12223453.

Mills L, Ndimande-Khoza MN, Velloza J, Atujuna M, Chitukuta M, Hosek S, Chauke H, Musara P, Mangxilana N, Mutero P, Makhale LM, Tauya T, Celum C, Delany-Moretlwe S; HPTN 082 study team.. Motivations for Starting and Stopping PrEP: Experiences of Adolescent Girls and Young Women in the HPTN 082 Trial. 2025. 29. 2408-2419. PMC12378742.

Zelaya DG, Janssen T, Windes B, Wheeler DP, Fields SD, Beauchamp G, Kahler CW, Wilton L, Mayer KH.. The Association of Positive Intersectionality Latent Classes with Psychosocial Factors and PrEP Outcomes in Black Men Who Have Sex with Men (HPTN 073). 0. . . .

Elbur AI, Donnell D, Hosek S, Dye B, Velloza J, Delany-Moretlwe S, Celum C. The Association Between Use of Adherence Support Interventions and Adherence to HIV Preexposure Prophylaxis Among Young South African and Zimbabwean Women in HPTN 082. 2025. 29. 2483-2494. PMC12360422.

He Q, Gao F, Dukes O, Delany-Moretlwe S, Zhang B.. Generalizing the intention-to-treat effect of an active control from historical placebo-controlled trials: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study. 0. 119. 2478-2492. PMC11694715.

Delany-Moretlwe S, Hanscom B, Guo X, Nkabiito C, Mandima P, Nahirya PN, Mpendo J, Bhondai-Mhuri M, Mgodi N, Berhanu R, Farrior J, Piwowar-Manning E, Ford SL, Hendrix CW, Rinehart AR, Rooney JF, Adeyeye A, Landovitz RJ, Cohen MS, Hosseinipour MC, Marzinke. Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084. 2025. 28. e26401. PMC11695207.

Perez-Brumer A, Schmidt R, Kennedy R, Lake JE, Villarreal YR, Bornstein S, Kuo I, Nieto O, Franks J, Denis C, El-Bassel N, Shoptaw S, Davidson P, Smith LR.. Centering autonomy and choice to support oral PrEP utilization among people who inject drugs: qualitative lessons from HPTN 094 INTEGRA. 2025. 19. 92. PMC11653907.

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083. 0. . . .

Gichane MW, Velloza J, Hosek S, Beauchamp G, Anderson P, Delany-Moretlwe S, Celum C; and the HPTN 082 Study Team. Hoping to Adhere? Examining the Relationship Between Hope and Pre-exposure Prophylaxis Willingness, Adherence, and Persistence Among Young Women in South Africa and Zimbabwe (HPTN 082). 2025. 29. 527-534. PMC11814051.

Tolley EE, Bula A, Chitukuta M, Ndimande-Khoza N, Etima J, Namey E, Kemigisha D, Makhale L, Tsidya M, Shoen M, Hosseinipour MC, Delany-Moretlwe S; HPTN 084 study team. Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084. 0. 19. . PMC11498703.

Orinda JO, Mudhune V, Opollo V, Mbeda C, Panchia R, Hamilton E, Dadabhai S, Reynolds D, Sandfort TGM; HPTN 075 study team. Interest in Oral Pre-exposure Prophylaxis Among Men Who Have Sex with Men and Transfeminine Persons in HPTN 075, a Multi-center HIV Prevention Study in Sub-Saharan Africa (2015-2017). 2025. 29. 411-419. PMC11813691.

Wendel KA, Erbelding EJ, Gaydos CA, Rompalo AM. Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. 2002. 35. 576-80. .

Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of Enrollment in a Preventive HIV Vaccine Trial: Hypothetical Versus Actual Willingness and Barriers to Participation. 2004. 36. 604-12. .